laboratory specialized in the treatment of rare neurological diseases

« A disruptive technology, which can be applied in the treatment of numerous conditions »

Inclusion of the first patient in the phase II clinical study that aims to test THN102 in patients affected by narcolepsy
Download PDF File (260 Ko)

Theranexus has obtained an orphan drug designation from the FDA for THN102 in the treatment of narcolepsy
Download PDF File (428 Ko)

Theranexus and its partners receive support from the FUI (French Inter-ministry Fund) for their project, Cx-COG
Download PDF File (149 Ko)

Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS)
Download PDF File (174 Ko)

Preclinical results published in the specialist medical journal Sleep, Phase II entry of THN102
Download PDF File (111 Ko)